Zura Bio Limited has 14 Schedule 13D or 13G filings on record since 2025-07-16. 4 holders' latest filing reports 5% or more of class a ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| AI Biotechnology LLC | 18.2% | 19,699,071 | SCHEDULE 13D/A, 2026-03-02 | 2026-02-26 |
| Athanor Capital | 15.7% | 11,581,402 | SCHEDULE 13D, 2026-01-27 | 2026-01-23 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 9,816,384 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Suvretta Capital Management, LLC | 9.9% | 9,524,263 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
| Jpmorgan Chase & Co | 4.7% | 4,471,316 | SCHEDULE 13G/A, 2026-05-06 | 2026-04-30 |
| Great Point Partners, LLC | 4.44% | 4,215,930 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Deep Track Capital, LP | 0.4% | 259,014 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Purpose of Transaction (Item 4)
Athanor Capital
The securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through 4(j) of Schedule 13D. The Reporting Persons may, from time to time, review their investment in the Issuer and may engage in discussions with management or the board of directors of the Issuer regarding the Issuer's business, operations and prospects, subject to applicable law. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or whether to adopt plans or proposals of the type specified above or otherwise.Item 4 of the SCHEDULE 13D filed 2026-01-27
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | Jpmorgan Chase & Co. | 7.5% | SCHEDULE 13G |
| 2025-08-14 | Deep Track Capital, LP | 7.13% | SCHEDULE 13G/A |
| 2025-08-14 | Venrock Healthcare Capital Partners III, L.P. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 0.4% | SCHEDULE 13G/A |
| 2025-11-14 | Great Point Partners, LLC | 5.87% | SCHEDULE 13G/A |
| 2026-01-02 | Athanor Capital | 15.7% | SCHEDULE 13G |
| 2026-01-27 | Athanor Capital | 15.7% | SCHEDULE 13D |
| 2026-02-13 | Suvretta Capital Management, LLC | 8.6% | SCHEDULE 13G/A |
| 2026-02-17 | Great Point Partners, LLC | 5.18% | SCHEDULE 13G/A |
| 2026-03-02 | AI Biotechnology LLC | 18.2% | SCHEDULE 13D/A |
| 2026-05-06 | Jpmorgan Chase & Co | 4.7% | SCHEDULE 13G/A |
| 2026-05-12 | Suvretta Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Great Point Partners, LLC | 4.44% | SCHEDULE 13G/A |
| 2026-05-15 | Venrock Healthcare Capital Partners III, L.P. | 9.9% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Zura Bio Limited. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.